Inozyme Pharma - רווח נקי למניה אחת בשנים עשר החודשים האחרונים INZY

Historical EPS YoY TTM dynamics demonstrate the impact of supply chain disruptions on Inozyme Pharma, Inc. (INZY). The current value of 33.60 serves as a baseline performance metric, which relies on the success of clinical trials for enzyme replacement therapy targeting orphan diseases. Meanwhile, environmental stability is ensured by medical sanctions exemptions and strict oversight from the FDA and EMA regulators.
Inozyme Pharma - פילוחים אנליטיים ומדדי מפתח (INZY)

This indicator determines the net income growth rate per share over the last twelve months relative to the previous year. The metric aggregates operational efficiency, allowing for an assessment of return on equity dynamics through the year-over-year change in EPS (TTM). Rising values signal a strengthening of the asset's fundamental value. For Inozyme Pharma, Inc. (INZY), negative trends at the R&D stage reflect high development costs; however, a future patent for the treatment of rare diseases could sharply reverse this vector due to the high margins of exclusive drugs.